Search research articles
Contact Us
Filters
Showing results (61-70 of 158) with videos related to
Page
of 16
Sort By:
Surgical Oncology Clinics of North America
|
May 14, 2019
Future Research Goals in Immunotherapy
Tyler W Hulett, Bernard A Fox, David J Messenheimer, et al.
Journal of Translational Medicine
|
April 8, 2021
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020
Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2017
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
David J Messenheimer, Shawn M Jensen, Michael E Afentoulis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 9, 2021
Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
Michele Maio, Christian Blank, Andrea Necchi, et al.
Journal of Translational Medicine
|
April 17, 2014
Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory T cells
Wei Ye, Yun Xing, Christopher Paustian, et al.
Oncoimmunology
|
November 20, 2012
Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs
Yongxiang Yi, Zhenxian Zhou, Su Shu, et al.
Clinical & Translational Immunology
|
May 20, 2016
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer
Ryan Montler, R Bryan Bell, Colin Thalhofer, et al.
Journal for Immunotherapy of Cancer
|
April 6, 2018
Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination
Tyler W Hulett, Shawn M Jensen, Phillip A Wilmarth, et al.
Oncoimmunology
|
May 13, 2026
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC)
Rachel E Sanborn, Shawn M Jensen, Christopher Paustian, et al.
Frontiers in Immunology
|
October 14, 2022
OX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines
Rebekka Duhen, Michael Beymer, Shawn M Jensen, et al.
Page
of 16
Search research articles
Search
Showing results (61-70 of 158) with videos related to
Sort By:
Page
of 16
Surgical Oncology Clinics of North America
|
May 14, 2019
Future Research Goals in Immunotherapy
Tyler W Hulett, Bernard A Fox, David J Messenheimer, et al.
Journal of Translational Medicine
|
April 8, 2021
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020
Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 1, 2017
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
David J Messenheimer, Shawn M Jensen, Michael E Afentoulis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 9, 2021
Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!
Michele Maio, Christian Blank, Andrea Necchi, et al.
Journal of Translational Medicine
|
April 17, 2014
Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory T cells
Wei Ye, Yun Xing, Christopher Paustian, et al.
Oncoimmunology
|
November 20, 2012
Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs
Yongxiang Yi, Zhenxian Zhou, Su Shu, et al.
Clinical & Translational Immunology
|
May 20, 2016
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer
Ryan Montler, R Bryan Bell, Colin Thalhofer, et al.
Journal for Immunotherapy of Cancer
|
April 6, 2018
Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination
Tyler W Hulett, Shawn M Jensen, Phillip A Wilmarth, et al.
Oncoimmunology
|
May 13, 2026
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC)
Rachel E Sanborn, Shawn M Jensen, Christopher Paustian, et al.
Frontiers in Immunology
|
October 14, 2022
OX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines
Rebekka Duhen, Michael Beymer, Shawn M Jensen, et al.
Page
of 16